SCHEMBL6794773

SCHEMBL6794773

O=C(Nc1ccc(Cn2ccnc2)cc1)c1ccccc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
HIF1A Q16665 3/20 0.49
EPAS1 Q99814 3/20 0.49
PTGS1 P23219 1/20 0.49
APOB P04114 2/20 0.49
MTTP P55157 2/20 0.49
CYP19A1 P11511 1/20 0.48
SMO Q99835 1/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
CYP17A1 P05093 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
KDR P35968 1/20 0.47
WDR5 P61964 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
NR3C1 P04150 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796230 0.90 HMOX1 (0.51) ALDH1A1PTGS1APOBMTTPSMO
SCHEMBL7137493 0.88 CYP19A1 (0.49) HIF1AEPAS1CYP19A1CYP17A1CYP11B1
SCHEMBL6794124 0.82 ALDH1A1 (0.53) ALDH1A1PTGS1APOBMTTPSMO
SCHEMBL6789828 0.81 PTGS1 (0.58) ALDH1A1PTGS1APOBMTTPGAA
SCHEMBL6788420 0.80 MTTP (0.57) ALDH1A1APOBMTTPGAAKDR
SCHEMBL6788109 0.80 MTTP (0.56) ALDH1A1PTGS1APOBMTTPGAA
SCHEMBL6791269 0.80 PTGS1 (0.59) ALDH1A1PTGS1APOBMTTPGAA
SCHEMBL18132582 0.79 CYP19A1 (0.60) ALDH1A1CYP19A1KDM4EMAPTCYP17A1
SCHEMBL3729112 0.79 NR1H4 (0.58) ALDH1A1PTGS1APOBMTTPSMN1; SMN2
SCHEMBL6791009 0.78 TRPV1 (0.55) ALDH1A1PTGS1APOBMTTPSMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 ALDH1A1 1427/4885HIF1A 4361/4885EPAS1 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.